natgillin/translations-raw huggingface dataset:
1.216 antiretroviralterapi-naive patienter med plasma hiv-1-RNA ved baseline >5.000 kopier/ml blev i 48 uger allokeret til Viramune 400 mg én gang daglig, Viramune 200 mg to gange daglig, efavirenz 600 mg én gang daglig eller Viramune (400 mg) og efavirenz (800 mg) én gang daglig, plus stavudin og lamivudin.
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA > 5,000 copies/ml at baseline were assigned to Viramune 400 mg once daily, Viramune 200 mg twice daily, efavirenz 600 mg once daily, or Viramune (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
Denne optrapningsperiode periode har vist sig at mindske hyppigheden af udslæt og bør derfor benyttes.
This lead-in period should be used because it has been found to lessen the frequency of rash.
Følgende bivirkninger er set hos patienter i vedligeholdelsesbehandling med Viramune depottabletter én gang dagligt:
The side effects described below have been experienced by patients given Viramune prolonged-release tablets once daily in the maintenance phase:
Nevirapin har en gennemsnitlig EC50-værdi (koncentration for 50 % hæmmet) på 63 nM mod et panel af gruppe M hiv-1 isolater fra typerne A, B, C, D, F, G og H, og de cirkulerende rekombinante former (CRF), CRF01_AE, CRF02_AG og CRF12_BF replikeret i humane embryonale nyre 293-celler.
Nevirapine had a median EC50 value (50% inhibitory concentration) of 63 nM against a panel of group M HIV-1 isolates from clades A, B, C, D, F, G, and H, and circulating recombinant forms (CRF), CRF01_AE, CRF02_AG and CRF12_BF replicating in human embryonic kidney 293 cells.
Patienter, der allerede får Viramune 200 mg to gange dagligt i kombination med andre antiretrovirale midler, kan skifte over til Viramune 400 mg depottabletter én gang dagligt i kombination med andre antiretrovirale midler uden en lead-in periode med Viramune 200 mg.
Patients already on a regimen of Viramune immediate-release twice daily in combination with other antiretroviral agents can be switched to Viramune 400 mg prolonged-release tablets once daily in combination with other antiretroviral agents without a lead-in period of Viramune immediate-release.
Hjælpestoffer: Indeholder saccharose, sorbitol, methylparahydroxybenzoat, propylparahydroxybenzoat (se indlægssedlen for yderligere information)
Excipients: includes sucrose, sorbitol, methyl parahydroxybenzoate, propyl parahydroxybenzoate (see leaflet for further information)
Hvis dit barn får nogen form for udslæt i denne periode, må dit barns dosis ikke øges, men du skal kontakte barnets læge i stedet.
If your child develops any rash during this period, do not increase the dose but consult your child's doctor.
Der er ikke udført lægemiddelinteraktionsstudier med telaprevir og nevirapin, men interaktionsstudier af telaprevir og en NNRTI med lignende metaboliseringsvej som nevirapin viste reducerede niveauer af begge.
No drug-drug interaction study of telaprevir with nevirapine has been conducted, however, interaction studies of telaprevir with an NNRTI with a similar metabolic pathway as nevirapine demonstrated reduced levels of both.
Viramune 100 mg depottabletter fås i plastbeholder med 90 depottabletter.
Viramune 100 mg prolonged-release tablets are supplied in bottles with 90 prolongedrelease tablets.
Viramune fås også som 200 mg tabletter til ældre børn og især unge, der vejer over 50 kg eller har en legemsoverfladeareal på mere end 1,25 m².
Viramune is also available as 200 mg tablets for older children, particularly adolescents, weighing more than 50 kg or having a body surface of more than 1.25 m2.
Der er bivirkninger, som kræver afbrydelse af Viramune-behandling, se pkt.
There are toxicities that require interruption of Viramune therapy (see section 4.4).
Resultatet af et 48-ugers sydafrikansk studie BI1100.1368 bekræftede, at i patientgrupperne doseret med 4 mg/kg og 150 mg/m² nevirapin var dosis veltolereret og effektiv i behandlingen af antiretroviralnaive pædiatriske patienter.
Results of a 48-week analysis of the South African study BI 1100.1368 confirmed that the 4/7 mg/kg and 150 mg/m2 nevirapine dose groups were well tolerated and effective in treating antiretroviral naive paediatric patients.
Patienterne skal instrueres i, at de ikke må starte med Viramune depottabletter, før et eventuelt udslæt opstået i den 14-dages optrapningsperiode med Viramune med umiddelbar frigivelse, er forsvundet.
Patients should be instructed that they should not begin Viramune prolonged-release tablets until any rash that has occurred during the 14-day lead-in period of Viramune immediate-release has resolved.
- Øvrige indholdsstoffer: - carbomer, - methylparahydroxybenzoat, - propylparahydroxybenzoat, - sorbitol, - saccharose, - polysorbat 80, - natriumhydroxid og - vand.
- The other ingredients are: carbomer, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sorbitol, sucrose, polysorbate 80, sodium hydroxide and water.
Beregning af mængden af Viramune oral suspension (50 mg/5 ml) til en pædiatrisk dosering baseret på dosen 150 mg/m² legemsoverfladeareal:
Calculation of the volume of Viramune oral suspension (50 mg/5 ml) required for paediatric dosing on a body surface basis of 150 mg/m
Beholderen indeholder 30 depottabletter.
Bottles contain 30 prolonged-release tablets.
Samtidig prednisonbrug (40 mg/dag i de første 14 dage af Viramune administrationen) har vist sig ikke at nedsætte tilfældene af nevirapin-associeret udslæt, og kan være associeret med en stigning tilfælde og alvorlighed af udslæt under de første 6 uger af nevirapin-behandlingen.
Concomitant prednisone use (40 mg/day for the first 14 days of Viramune administration) has been shown not to decrease the incidence of nevirapine-associated rash, and may be associated with an increase in incidence and severity of rash during the first 6 weeks of nevirapine therapy.
Der sås ikke signifikant forskel på virkningen i ”nevirapin 2 gange daglig”-regimegruppen og efavirenzregimegruppen (p = 0,091) bedømt ud fra behandlingssvigt, eller tilfælde af behandlingssvigt, herunder virologisk svigt.
The nevirapine twice daily regimen and the efavirenz regimen were not significantly different (p=0.091) in terms of efficacy as measured by treatment failure, or any component of treatment failure including virological failure.
200 (2 x 100 mg) 300 (3 x 100 mg)
200 (2 x 100 mg)
Nevirapin er en ikke-nukleosid revers transkriptasehæmmer (NNRTI) af hiv-1.
Nevirapine is a NNRTI of HIV-1.
Nevirapin har vist sig at inducere leverens cytokrom P450-metaboliske enzymer.
Nevirapine has been shown to be an inducer of hepatic cytochrome P450 metabolic enzymes.
Nevirapins anti-hiv-1-aktivitet blev in vitro hæmmet af anti-HBV-midlet adefovir og af anti-HCV-midlet ribavirin.
The anti-HIV-1 activity of nevirapine was antagonized by the anti-HBV medicinal product adefovir and by the anti-HCV medicinal product ribavirin in vitro.
Baseline (gennemsnit) n = 503
Baseline (mean) n=503
Ketoconazol AUC  0,28 (0,20-0,40) Ketoconazol Cmin ND Ketoconazol Cmax  0,56 (0,42-0,73)
Ketoconazole AUC  0.28 (0.20Ketoconazole Cmin ND Ketoconazole Cmax  0.56 (0.42
Immunsystemet Almindelig:
Immune system disorders
INFORMATION I BRAILLESKRIFT Viramune 200 mg
INFORMATION IN BRAILLE Viramune 200 mg
I humane in vivo studier og in vitro studier med humane levermikrosomer har vist, at nevirapin i høj grad biotransformeres via cytokrom P450 (oxidativ) metabolisme til adskillige hydroxylerede metabolitter.
Biotransformation and elimination: In vivo studies in humans and in vitro studies with human liver microsomes have shown that nevirapine is extensively biotransformed via cytochrome P450 (oxidative) metabolism to several hydroxylated metabolites.
Hepatobiliært
Hepato-biliary
Ved behandling af patienter, der er smittet med tuberkulose, som samtidig får Viramune, bør anvendelse af rifabutin overvejes istedet.
Physicians needing to treat patients co-infected with tuberculosis and using a Viramune containing regimen may consider coadministration of rifabutin instead.
Den geometriste middelværdi ratio for Viramune i depotform i forhold til Viramune 200 mg var ~90 % for Cmin,ss og for AUCss med 90 % konfidensintervaller inden for 80 %-125 %; ratio for Cmax,ss var lavere og konsistent med én gang dagligt depotdoseringsform.
The observed geometric mean ratios of Viramune prolonged-release to Viramune immediate-release were ~90 % for Cmin,ss and AUCss with 90% confidence intervals within 80 %-125 %; the ratio for Cmax,ss was lower and consistent with a once-daily prolonged-release dosage form.
Risikoen for hepatiske bivirkninger er størst i de første 6 uger af behandlingen.
The risk of hepatic reactions is greatest in the first 6 weeks of therapy.
Sådanne reaktioner kan opstå i form af anafylaksi (en alvorlig form for allergisk reaktion) med symptomer som: - udslæt - hævelse i ansigtet - vejrtrækningsbesvær (bronkospasme - astmalignende gener) - anafylaktisk shock
Such reactions may appear in the form of anaphylaxis (a severe form of allergic reaction) with symptoms such as: - rash - swelling of the face - difficulty breathing (bronchial spasm) - anaphylactic shock
Følgende bivirkninger, som kan være forårsaget af indgivelsen af Viramune, er blevet rappoteret.
The following adverse reactions which may be causally related to the administration of Viramune have been reported.
Ingen signifikant virkning på rifabutin og Viramune gennemsnitlige farmakokinetiske (PK) parametre er set.
No significant effect on rifabutin and Viramune mean PK parameters is seen.
Viramune er kontraindiceret hos patienter med alvorlig hepatisk insufficiens (ChildPugh C, se pkt.
Viramune is contraindicated in patients with severe hepatic impairment (Child-Pugh C, see section 4.3).
Nevirapin skal seponeres permanent hos enhver patient, som udvikler et alvorligt udslæt eller udslæt ledsaget af konstitutionelle symptomer (såsom feber, blæredannelse, orale læsioner, conjunctivitis, ødemer i ansigt, muskel- eller ledsmerter eller generel utilpashed) inkluderende Stevens-Johnsons syndrom eller toksisk epidermal nekrolyse.
Nevirapine must be permanently discontinued in any patient experiencing severe rash or a rash accompanied by constitutional symptoms (such as fever, blistering, oral lesions, conjunctivitis, facial oedema, muscle or joint aches, or general malaise), including Stevens-Johnson syndrome, or toxic epidermal necrolysis.
Lactose: Ved den maksimale, anbefalede daglige dosis af Viramune tabletter indtages 636 mg lactose.
Lactose: Viramune tablets contain 636 mg of lactose per maximum recommended daily dose.
Stevens-Johnsons syndrom/toksisk epidermal nekrolyse (som kan være letal) (0,2 %), angioødem, urticaria
Uncommon Stevens-Johnson Syndrome/toxic epidermal necrolysis (which may be fatal) (0.2 %), angioedema, urticaria
Efter 14 dage er den sædvanlige dosis én Viramune 400 mg depottablet én gang dagligt.
After 14 days, the usual dose is one 400 mg prolonged-release tablet once a day.
Efter 14 dage er dosis normalt 1 tablet på 200 mg 2 gange daglig.
After 14 days, the usual dose is one 200 mg tablet twice a day.
Resultatet tyder på, at ved at supplere nevirapinbehandlingen med en ekstra dosis på 200 mg Viramune efter hver dialysebehandling kan effekten af dialyse på nevirapinclearance afhjælpes.
The results suggest that supplementing nevirapine therapy with an additional 200 mg dose of Viramune following each dialysis treatment would help offset the effects of dialysis on nevirapine clearance.
Patienter med svær hepatisk insufficiens (Child-Pugh C) eller der forud for behandling har ASAT eller ALAT > 5 ULN før baseline ASAT/ALAT er stabiliseret < 5 ULN.
Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN.
Den kliniske virkning af Viramune depottabletter er baseret på 48 ugers data fra et randomiseret, dobbeltblindet, dobbeltdummy-, fase III-studie (VERxVE - studie 1100.1486) med behandlingsnaive patienter og 24 ugers data fra et randomiseret, åben-label studie hos patienter, der er overgået fra to gange dagligt Viramune 200 mg tabletter til én gang dagligt Viramune depottabletter (TRANxITION -studie 1100.1526).
The clinical efficacy of Viramune prolonged-release is based on 48-week data from a randomised, double-blind, double-dummy phase 3 study (VERxVE - study 1100.1486) in treatment-naïve patients and on 24-week data from a randomised, open-label study in patients who transitioned from Viramune immediate-release tablets administered twice daily to Viramune prolonged-release tablets administered once daily (TRANxITION - study 1100.1526).
Absolut biotilgængelighed hos 12 raske voksne efter en enkelt dosis var 93±9 % (gennemsnitlig SD) efter en 50 mg tablet og 91±8 % efter peroral opløsning.
Absolute bioavailability in 12 healthy adults following single-dose administration was 93  9 % (mean SD) for a 50 mg tablet and 91  8% for an oral solution.
Absolut biotilgængelighed hos 12 raske voksne efter en enkelt dosis var 93±9% (gennemsnitlig SD) efter en 50 mg tablet og 91±8% efter peroral opløsning.
Absolute bioavailability in 12 healthy adults following single-dose administration was 93  9 % (mean SD) for a 50 mg tablet and 91  8 % for an oral solution.
HDPE-beholder (high density polyethylen) med plastiklåg og folieforsegling.
High density polyethylene (HDPE) plastic bottle, with a plastic cap and an induction foil seal liner.
ANTIBIOTIKA Clarithromycin 500 mg 2 gange dagligt
ANTIBIOTICS Clarithromycin 500 mg BID
Der sås ikke signifikant forskel på virkningen i ”nevirapin 2 gange daglig”regimegruppen og efavirenz-regimegruppen (p = 0,091) bedømt ud fra behandlingssvigt, eller tilfælde af behandlingssvigt, herunder virologisk svigt.
The nevirapine twice daily regimen and the efavirenz regimen were not significantly different (p= 0.091) in terms of efficacy as measured by treatment failure, or any component of treatment failure including virological failure.
Til mindre børn findes en oral suspension (flydende form).
For smaller children an oral suspension liquid form is available.
Rekommendationer ved coadministration med Viramune
Recommendations concerning coadministration
Baseline (gennemsnit) n = 505
Baseline (mean) n=505
Mosteller-formel: Legemsoverfladeareal (m
Mosteller Formula: BSA (m
Viramune oral suspension indeholder 150 mg saccharose pr. ml.
Viramune oral suspension contains 150 mg sucrose per ml.
Den terapeutiske virkning af stoffer, der metaboliseres af P450 bør derfor monitoreres nøje ved co-administration med nevirapin.
Careful monitoring of the therapeutic effectiveness of P450 metabolised medicinal products is recommended when taken in combination with nevirapine.
200 mg
200 mg QD
Hos nogle patienter kan et hududslæt, der viser sig som blærer på huden, være alvorligt og livstruende (Stevens-Johnsons syndrom og toksisk epidermal nekrolyse) og dødsfald har fundet sted.
However, in some patients a rash, which appears as a blistering skin reaction, can be severe or life-threatening (Stevens-Johnson syndrome and toxic epidermal necrolysis) and deaths have been recorded.
Nevirapins AUC0-24,ss og Cmin,ss målt efter 19 dages fastende dosering af Viramune 400 mg depottabletter én gang dagligt, var henholdsvis ca. 80 % og 90 % af AUC0-24,ss og Cmin,ss målt ved dosering af Viramune 200 mg tabletter to gange dagligt.
The nevirapine AUC0-24,ss and Cmin,ss measured after 19 days of fasted dosing of Viramune 400 mg prolonged-release tablets once daily were approximately 80 % and 90 %, respectively, of the AUC0-24,ss and Cmin,ss measured when patients were dosed with Viramune 200 mg immediate-release tablets twice daily.
Tabel 2: Vedligeholdelsesfase med Viramune depottabletter
Table 2: Maintenance phase of Viramune prolonged-release
Studier med behandlingserfarne patienter
Studies in treatment-experienced patients
Følgende tilfælde har også været rapporteret, når Viramune er blevet taget i kombination med andre retrovirale midler: - fald i antal røde blodlegemer eller i blodplader - betændelse i bugspytkirtlen - nedsat eller abnorm følsomhed i huden
The following events have also been reported when Viramune has been used in combination with other antiretroviral agents: - decreased numbers of red blood cells or platelets - inflammation of the pancreas - decrease in or abnormal skin sensations
Til små børn og nyfødte, findes der en oral suspension.
For younger children starting from birth an oral suspension is available.
Da alvorlig og livstruende hepatotoksicitet i kontrollerede og ukontrollerede studier fortrinsvis er set hos patienter med en hiv-1-virusbelastning i plasma på 50 kopier/ml eller højere, skal nevirapin ikke initieres hos kvinder med CD4-celletal større end 250 celler/mm eller hos mænd med CD4-celletal større end
As serious and life threatening hepatotoxicity has been observed in controlled and uncontrolled studies predominantly in patients with a plasma HIV-1 viral load of 50 copies/ml or higher, nevirapine should not be initiated in adult females with CD4 cell counts greater than 250 cells/mm
EU/1/97/055/009 [90 depottabletter]
EU/1/97/055/009 [90 prolonged-release]
Samtidig behandling med naturlægemidler indeholdende perikon (Hypericum perforatum) pga. risiko for nedsat plasmakoncentration og reduceret klinisk effekt af nevirapin (Se pkt.
Coadministration with herbal preparations containing St. John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine (see section 4.5).
Emtricitabin hæmmer ikke humane CYP-enzymer.
Emtricitabine is not an inhibitor of human CYP 450 enzymes.
Rifabutin 150 eller 300 mg 4 gange daglig
Rifabutin 150 or 300 mg QD
Fordi nevirapin fremkalder sin egen metabolisme ved multipel dosering, viser dette enkeltdosis studie ikke nødvendigvis den påvirkning af leveren, som ses ved multipel dosering (se pkt.
Because nevirapine induces its own metabolism with multiple dosing, this single dose study may not reflect the impact of hepatic impairment on multiple dose pharmacokinetics (see section
Til brug herfor anvendes den medfølgende dispenseringssprøjte.
This is assisted by the use of the supplied dispensing syringe.
Den anbefalede dosis Viramune er 20 ml (200 mg) oral suspension 1 gang daglig i de første 14 dage (denne optrapningsperiode bør benyttes, idet den har vist sig at mindske hyppigheden af udslæt) efterfulgt af 20 ml (200 mg) oral suspension 2 gange dagligt i kombination med mindst to antiretrovirale lægemidler.
The recommended dose for Viramune is 20 ml (200 mg) oral suspension once daily for the first 14 days (this lead-in period should be used because it has been found to lessen the frequency of rash), followed by 20 ml (200 mg) oral suspension twice daily, in combination with at least two additional antiretroviral agents.
Genotypisk analyse af isolater fra antiretroviralnaive patienter, der havde oplevet virologisk svigt (n=71) med nevirapin administreret én gang dagligt (n=25) eller to gange dagligt (n=46) i kombination med lamivudin og stavudin i 48 uger, viste, at isolater fra 8/25 henholdsvis 23/46 patienter indeholdt en eller flere af de følgende NNRTI-resistens-associerede substitutioner: Y181C, K101E, G190A, K103N, V106A/M, V108I, Y188C/L, A98G, F227L og M230L.
Genotypic analysis of isolates from antiretroviral naïve patients experiencing virologic failure (n=71) receiving nevirapine once daily (n=25) or twice daily (n=46) in combination with lamivudine and stavudine for 48 weeks showed that isolates from 8/25 and 23/46 patients, respectively, contained one or more of the following NNRTI resistance-associated substitutions: Y181C, K101E, G190A/S, K103N, V106A/M, V108I, Y188C/L, A98G, F227L and M230L.
Det multinationale 2NN-studie med Viramune 200 mg indeholdt et farmakokinetisk substudie med 1077 patienter, hvoraf de 391 var kvinder.
In the multinational 2NN study with Viramune immediate-release, a population pharmacokinetic substudy of 1077 patients was performed that included 391 females.
Patienter, der skifter fra Viramune tabletter til Viramune depottabletter I fase III-studiet TRANxITION (studie 1100.1526) blev sikkerhed og antiviral aktivitet hos patienter, der skifter fra Viramune 200 mg til Viramune i depotform evalueret.
Patients switching from Viramune immediate-release to Viramune prolonged-release TRANxITION (study 1100.1526) is a Phase 3 study to evaluate safety and antiviral activity in patients switching from Viramune immediate-release to Viramune prolonged-release.
Viramune indeholder saccharose, sorbitol, methylparahydroxybenzoat, propylparahydroxybenzoat og natrium
Viramune contains sucrose, sorbitol, methyl parahydroxybenzoate, propyl parahydroxybenzoate and sodium
- tidligere ubehandlede patienter, der har forhøjede CD4-celletal ved starten af behandling med Viramune (kvinder med over 250 celler/mm 3, mænd med over 400 celler/mm - tidligere behandlede patienter med påviselig hiv-1 plasma viral niveau og højere CD4-celletal ved behandlingsstart med Viramune (kvinder mere end 250 celler/mm 3, mænd mere end 400
- treatment-naïve patients with higher CD4 cell counts at the start of Viramune therapy (women more than 250 cells/mm³, men more than 400 cells/mm³) - pre-treated patients with detectable HIV-1 plasma viral load and higher CD4 cell counts at the start of Viramune therapy (women more than 250 cells/mm³, men more than 400 cells/mm³)
3 12 gange større risiko for symptomatisk leverpåvirkning sammenlignet med kvinder med CD4-celletal <250 celler/mm
3 had a 12 fold higher risk of symptomatic hepatic adverse reactions compared to women with CD4 counts <250 cells/mm
Farvede patienter (n = 80/gruppe) i studie 1100.1486 havde ca. 30 % højere trough-koncentrationer end kaukasiske patienter (250-325 patienter/gruppe) med Viramune 200 mg såvel som med Viramune depottabletter over 48 ugers behandling med 400 mg/dag.
Black patients (n=80/group) in study 1100.1486 showed approximately 30% higher trough concentrations than Caucasian patients (250-325 patients/group) in both the Viramune immediate-release and Viramune prolonged-release treatment groups over 48 weeks of treatment at 400 mg/day.
In vitro er der set hurtig udvikling af hiv-stammer, som er krydsresistente over for NNRT-hæmmere.
Rapid emergence of HIV-strains which are cross-resistant to NNRTIs has been observed in vitro.
3 for mænd) ved initiering af nevirapin-behandling, og som har et detekterbar plasmaniveau af hiv-1-RNA - dvs. ≥50 kopier/ml - har en højere risiko for leverpåvirkninger.
3 in adult males) at the initiation of nevirapine therapy are associated with a greater risk of hepatic adverse reactions if the patient has detectable plasma HIV-1 RNA - i.e. a concentration ≥ 50 copies/ml - at the initiation of nevirapine.
Informer din læge, hvis du oplever nogen af de følgende kliniske symptomer på leverskade - appetitløshed - kvalme - opkastning - huden bliver gul (gulsot) - mavesmerter.
Tell your doctor if you experience any of the following clinical symptoms of liver damage: - loss of appetite - feeling sick (nausea) - vomiting - yellow skin (jaundice) - abdominal pain.
Behandling med nevirapin må ikke genstartes efter svær lever-, hud- eller overfølsomhedsreaktioner (se pkt.
Nevirapinemust not be restarted following severe hepatic, skin or hypersensitivity reactions (see section 4.3).
Det anbefales ikke at coadministrere fosamprenavir og Viramune, hvis fosamprenavir ikke co-administreres sammen med ritonavir (se pkt.
It is not recommended to coadminister fosamprenavir and Viramune if fosamprenavir is not coadministered with ritonavir (see section 4.4).
I et masse-balance/ekskretionsstudie med 8 raske, frivillige, mandlige forsøgspersoner, som blev behandlet indtil steady state med nevirapin 200 mg 2 gange dagligt efterfulgt af en enkelt dosis på 50 mg af 14C-nevirapin blev tilnærmelsesvis 91,4±10,5 % af den radioaktivt mærkede dosis genfundet: I urinen (81,3±11,1 %) hvilket repræsenterer den primære ekskretionsvej sammenlignet med fæces (10,1±1,5 %).
In a mass balance/excretion study in eight healthy male volunteers dosed to steady state with nevirapine 200 mg given twice daily followed by a single 50 mg dose of 14C-nevirapine, approximately 91.4  10.5 % of the radiolabelled dose was recovered, with urine (81.3  11.1 %) representing the primary route of excretion compared to faeces (10.1  1.5 %).